Our present study examined the expression of HHLA2 in ovarian cancer and analysed its relationship with clinicopathologic features and prognosis to further explore its role in ovarian cancer, providing a primary foundation for the discovery of new immunotherapeutic targets for ovarian cancer. This evidence concerns the gene HHLA2 and ovarian carcinoma.